Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
McKinsey
Mallinckrodt
Baxter
Harvard Business School

Last Updated: January 27, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Urapidil


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Urapidil?

Urapidil is an investigational drug.

There have been 14 clinical trials for Urapidil. The most recent clinical trial was a Phase 3 trial, which was initiated on June 15th 2017.

The most common disease conditions in clinical trials are Hypertension, Stroke, and Hemorrhage. The leading clinical trial sponsors are National Health and Medical Research Council, Australia, The George Institute, and University Hospital, Strasbourg, France.

There are nine hundred and sixty-four US patents protecting this investigational drug and eight international patents.

Recent Clinical Trials for Urapidil
TitleSponsorPhase
Propofol EC50 for Inducing Loss of Consciousness in General Combined Epidural AnesthesiawangjianglingN/A
Efficacy and Safety Profile of Remimazolam-alfentanil Combination for ERCP SedationTianjin Nankai HospitalN/A
Intensive Ambulance-delivered Blood Pressure Reduction in Hyper-Acute Stroke TrialFirst Affiliated Hospital of Chengdu Medical CollegePhase 3

See all Urapidil clinical trials

Clinical Trial Summary for Urapidil

Top disease conditions for Urapidil
Top clinical trial sponsors for Urapidil

See all Urapidil clinical trials

US Patents for Urapidil

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Urapidil ⤷  Try it Free Double-acylated GLP-1 derivatives Novo Nordisk A/S (Bagsvaerd, DK) ⤷  Try it Free
Urapidil ⤷  Try it Free Methods and compositions for treating infection UNIVERSITY OF ROCHESTER (Rochester, NY) UNIVERSITY OF KANSAS (Lawrence, KS) ⤷  Try it Free
Urapidil ⤷  Try it Free Double-acylated GLP-1 derivatives Novo Nordisk A/S (Bagsvaerd, DK) ⤷  Try it Free
Urapidil ⤷  Try it Free Derivatives of GLP-1 like peptides, and uses thereof Novo Nordisk A/S (Bagsvaerd, DK) ⤷  Try it Free
Urapidil ⤷  Try it Free Ultra-pure agonists of guanylate cyclase C, method of making and using same SYNERGY PHARMACEUTICALS, INC. (New York, NY) ⤷  Try it Free
Urapidil ⤷  Try it Free Compositions containing polymeric, ionic compounds comprising imidazolium groups BASF SE (Ludwigshafen, DE) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Urapidil

Drugname Country Document Number Estimated Expiration Related US Patent
Urapidil China CN104519902 2032-05-08 ⤷  Try it Free
Urapidil European Patent Office EP2846823 2032-05-08 ⤷  Try it Free
Urapidil Spain ES2770599 2032-05-08 ⤷  Try it Free
Urapidil Japan JP2015517477 2032-05-08 ⤷  Try it Free
Urapidil Japan JP6250034 2032-05-08 ⤷  Try it Free
Urapidil World Intellectual Property Organization (WIPO) WO2013167454 2032-05-08 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
McKinsey
Mallinckrodt
Baxter
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.